Acute kidney injury in patients hospitalized with COVID-19 in Wuhan, China: a single-center retrospective observational study.
10.12122/j.issn.1673-4254.2021.02.01
- Author:
Guanhua XIAO
1
;
Hongbin HU
2
;
Feng WU
2
;
Tong SHA
2
;
Zhenhua ZENG
2
;
Qiaobing HUANG
3
;
Haijun LI
4
;
Jiafa HAN
4
;
Wenhong SONG
4
;
Zhongqing CHEN
2
;
Shumin CAI
2
Author Information
1. Department of Respiratory and Critical Care Medicine, Southern Medical University, Guangzhou 510515, China.
2. Department of Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
3. Guangdong Provincial Key Laboratory of Shock and Microcirculation, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, China.
4. Department of Radiology, Hankou Hospital of Wuhan, Wuhan 430012, China.
- Publication Type:Observational Study
- Keywords:
acute kidney injury;
coronavirus disease 2019;
kidney function
- MeSH:
Acute Kidney Injury/epidemiology*;
Aged;
COVID-19;
China/epidemiology*;
Humans;
Male;
Retrospective Studies;
SARS-CoV-2
- From:
Journal of Southern Medical University
2021;41(2):157-163
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To assess the predictors and outcomes of acute kidney injury (AKI) among patients with coronavirus disease 2019 (COVID-19).
OBJECTIVE:This retrospective observational study was conducted among patients with a confirmed diagnosis of COVID-19 admitted to Hankou Hospital between January, 5 and March 8, 2020. We evaluated the association of AKI with the demographic and biochemical parameters and clinical outcomes of the patients using univariate regression analysis.
OBJECTIVE:Atotal of 287 COVID-19 patients, including 55 with AKI and 232 without AKI, were included in the analysis. Compared with the patients without AKI, the patients with AKI were older, predominantly male, and were more likely to have hypoxia and pre-existing hypertension and cerebrovascular diseases. The patients with AKI also had higher levels of white blood cells, D-dimer, aspartate aminotransferase, total bilirubin, creatine kinase, lactate dehydrogenase, procalcitonin, C-reactive protein, a higher prevalence of hyperkalemia, lower lymphocyte counts, and higher chest computed tomographic scores. The incidence of stage 1 AKI was 14.3% and that of stage 2 or 3 AKI was 4.9%. The patients with AKI had much higher mortality rate than those without AKI.
OBJECTIVE:AKI is an important complication of COVID-19. An older age, a male gender, multiple pre- existing comorbidities, lymphopenia, increased infection indicators, elevated D-dimer, and impaired heart and liver functions are all potential risk factors ofAKI. COVID- 19 patients with AKI that progresses into stages 2 or 3 AKI have a high mortality rate. Prevention of AKI and monitoring kidney function is critical in the care of COVID-19 patients.
